Phase I and II trials focus on drug combination slowing development of resistance inhibiting BRAF

Share :
Published: 29 Sep 2012
Views: 3958
Prof Yossef Yarden - Weizmann Institute of Science, Israel.

Promising new data on drug combinations to treat metastatic melanoma are presented at a press conference from the ESMO 2012 Congress of the European Society for Medical Oncology in Vienna.


“These studies exemplify an important landmark of some tumours, which has emerged from recent laboratory research: the presence of specific mutations, such as the BRAF mutation in metastatic melanoma which exposes an Achilles' heel--MEK in this case,” said Prof Yossef Yarden from the Weizmann Institute of Science, Israel.


ecancerNews Coverage from ESMO 2012